Κύπρος -
Ελληνικά -
Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας
solu-medrone 125mg/vial powder & solvent for solution for injection
pfizer hellas ae (0000003442) 243 messoghion avenue, neo psychiko, athens, 15451 - methylprednisolone sodium succinate - powder & solvent for solution for injection - 125mg/vial - methylprednisolone sodium succinate (0002375033) 165,8mg
Κύπρος -
Ελληνικά -
Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας
solu-medrone 1000mg/vial powder & solvent for solution for injection
pfizer hellas ae (0000003442) 243 messoghion avenue, neo psychiko, athens, 15451 - methylprednisolone sodium succinate - powder & solvent for solution for injection - 1000mg/vial - methylprednisolone sodium succinate (0002375033) 1328mg
Κύπρος -
Ελληνικά -
Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας
bivelen 7.5mg film coated tablets
delorbis pharmaceuticals ltd (0000009620) 17 athinon street, ergates industrial area, lefkosia, 2081, 28629 - ivabradine oxalate - film coated tablets - 7.5mg - ivabradine oxalate (0134655808) 8,941mg
Κύπρος -
Ελληνικά -
Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας
bivelen 5mg film coated tablets
delorbis pharmaceuticals ltd (0000009620) 17 athinon street, ergates industrial area, lefkosia, 2081, 28629 - ivabradine oxalate - film coated tablets - 5mg - ivabradine oxalate (0134655808) 5,961mg
Ευρωπαϊκή Ένωση -
Ελληνικά -
EMA (European Medicines Agency)
byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - Οφθαλμολογικά - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
Ευρωπαϊκή Ένωση -
Ελληνικά -
EMA (European Medicines Agency)
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - Οφθαλμολογικά - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
Ευρωπαϊκή Ένωση -
Ελληνικά -
EMA (European Medicines Agency)
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - Οφθαλμολογικά - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).